Oric Pharmaceuticals   Report issue

For profit Phase 1
Founded: South San Francisco CA United States (2014)

Organization Overview

First Clinical Trial
2017
NCT03324555
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Oric Pharmaceuticals

Active Ingredients

Drugs in Phase 1 Trials (3)

enzalutamide (xtandi) (1 trial)

oric-101 (4 trials)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Prostatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 3